Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Improvement In Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy
Autore:
Nishimoto, N; Sasai, M; Shima, Y; Nakagawa, M; Matsumoto, T; Shirai, T; Kishimoto, T; Yoshizaki, K;
Indirizzi:
Osaka Univ, Dept Med Sci 1, Sch Hlth & Sport Sci, Suita, Osaka 5650871, Japan Osaka Univ Suita Osaka Japan 5650871 ort Sci, Suita, Osaka 5650871, Japan Osaka Univ, Dept Med Sci 3, Sch Hlth & Sport Sci, Suita, Osaka 5650871, Japan Osaka Univ Suita Osaka Japan 5650871 ort Sci, Suita, Osaka 5650871, Japan Juntendo Univ, Sch Med, Dept Pathol 2, Tokyo 113, Japan Juntendo Univ Tokyo Japan 113 , Sch Med, Dept Pathol 2, Tokyo 113, Japan
Titolo Testata:
BLOOD
fascicolo: 1, volume: 95, anno: 2000,
pagine: 56 - 61
SICI:
0006-4971(20000101)95:1<56:IICDBH>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
KAPOSIS-SARCOMA; DNA-SEQUENCES; INTERLEUKIN-6; CELLS; ASSOCIATION; IMMUNOASSAY; LEUKEMIA; GROWTH; HIV;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Nishimoto, N Osaka Univ, Dept Med Sci 1, Sch Hlth & Sport Sci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan Osaka Univ 2-2 Yamadaoka Suita Osaka Japan 5650871 871, Japan
Citazione:
N. Nishimoto et al., "Improvement In Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy", BLOOD, 95(1), 2000, pp. 56-61

Abstract

Castleman's disease, an atypical lymphoproliferative disorder, can be classified into 2 types: hyaline-vascular and plasma cell types according to the histologic features of the affected lymph nodes, The plasma cell type is frequently associated with systemic manifestations and is often refractory to systemic therapy including corticosteroids and chemotherapy, particularly in multicentric form. Dysregulated overproduction of interleukin-6 (IL-6)from affected lymph nodes is thought to be responsible for the systemic manifestations of this disease. Therefore, interference with IL-6 signal transduction may constitute a new therapeutic strategy for this disease. We used humanized anti-IL-6 receptor antibody (rhPM-1) to treat 7 patients with multicentric plasma cell or mixed type Castleman's disease, All patients hadsystemic manifestations including secondary amyloidosis in 3, With the approval of our institution's ethics committee and the consent of the patients, they were treated with 50 to 100 mg rhPM-1 either once twice weekly. immediately after administration of rhPM-1,fever and fatigue disappeared, and anemia as well as serum levels of C-reactive protein (CRP), fibrinogen, and albumin started to improve. After 3 months of treatment, hypergammaglobulinemia and lymphadenopathy were remarkably alleviated, as were renal functionabnormalities in patients with amyloidosis, Treatment was well tolerated with only transient leukopenia, Histopathologic examination revealed reducedfollicular hyperplasia and vascularity after rhPM-1 treatment. The pathophysiologic significance of IL-6 in Castleman's disease was thus confirmed, and blockade of the IL-6 signal by rhPM-1 is thought to have potential as a new therapy based on the pathophysiologic mechanism of multicentric Castleman's disease. (C) 2000 by The American Society of Hematology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/07/20 alle ore 05:50:30